➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
McKesson
Baxter
Merck

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

DEPO-PROVERA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Depo-provera, and what generic alternatives are available?

Depo-provera is a drug marketed by Pharmacia And Upjohn and is included in two NDAs.

The generic ingredient in DEPO-PROVERA is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Drug patent expirations by year for DEPO-PROVERA
Drug Prices for DEPO-PROVERA

See drug prices for DEPO-PROVERA

Drug Sales Revenue Trends for DEPO-PROVERA

See drug sales revenues for DEPO-PROVERA

Recent Clinical Trials for DEPO-PROVERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MU-JHU CAREPhase 4
University of California, San DiegoEarly Phase 1
Nationwide Children's HospitalPhase 4

See all DEPO-PROVERA clinical trials

Pharmacology for DEPO-PROVERA
Drug ClassProgestin

US Patents and Regulatory Information for DEPO-PROVERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn DEPO-PROVERA medroxyprogesterone acetate INJECTABLE;INJECTION 012541-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn DEPO-PROVERA medroxyprogesterone acetate INJECTABLE;INJECTION 020246-001 Oct 29, 1992 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn DEPO-PROVERA medroxyprogesterone acetate INJECTABLE;INJECTION 012541-003 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEPO-PROVERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn DEPO-PROVERA medroxyprogesterone acetate INJECTABLE;INJECTION 012541-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Pharmacia And Upjohn DEPO-PROVERA medroxyprogesterone acetate INJECTABLE;INJECTION 012541-003 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Baxter
Boehringer Ingelheim
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.